VEGFA and breast carcinoma: In breast cancer, the androgenic steroid compound androstene-3β,17α-diol could inhibit lung metastasis and increase the percentage of NK and plasma cells; this effect is accompanied with the decreased expression of vascular endothelial growth factor (VEGF) in the TME 196.